dorsaVi (ASX:DVL) - CEO, Dr Andrew Ronchi
CEO, Dr Andrew Ronchi
Source: North Road Physiotherapy
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • dorsaVi (DVL) has entered a master services agreement (MSA) with global medical technology, services and solutions provider Medtronic
  • DVL develops innovative motion analysis devices for use in clinical applications, elite sports and occupational health and safety
  • Through the new MSA, dorsaVi will progress its commercial relationship with Medtronic, following an initial evaluation agreement in December last year
  • The second-stage agreement is worth roughly US$330,000 (around A$435,000)
  • Over a rough twelve-month project timeframe, the companies will continue to analyse data on patients wearing dorsaVi medical-grade sensors in an effort to optimise the technology
  • dorsaVi shares are trading flat at 4.1 cents each

dorsaVi (DVL) has entered a master services agreement (MSA) with global medical technology, services and solutions provider Medtronic.

With offices in Australia, the U.S. and the U.K., dorsaVi develops innovative motion analysis devices for use in clinical applications, elite sports and occupational health and safety.

The company, through the new MSA, will now progress its commercial relationship with Medtronic, following an initial evaluation agreement between the companies in December last year.

Under the initial deal, Medtronic stand worked alongside leading clinicians to evaluate the effectiveness of dorsaVi’s technology in assessing patients undergoing surgical evaluation.

The second-stage agreement, worth roughly US$330,000 (around A$435,000), will see DVL work with Medtronic to perform further data capture and analysis in an effort to optimise its technology.

Over a rough twelve-month project timeframe, the companies will continue to analyse data on patients wearing dorsaVi medical-grade sensors.

dorsaVi CEO Dr Andrew Ronchi said he is delighted to advance the company’s relationship with Medtronic and to continue helping to achieve better clinical results for patients.

“This second-stage agreement is the continued evaluation of our technology, as it follows on from our work as part of the initial evaluation agreement signed in December 2020,” Dr Ronchi commented.

“Aligned with our channel partnership strategy, we are excited by the opportunities with Medtronic, a world-leading medical technology, services and solutions company.”

Headquartered in Dublin and with operations in 150 countries worldwide, Medtronic is focussed on alleviating pain, restoring health and extending life for millions of people around the world.

dorsaVi shares are trading flat at 4.1 cents at 12:02 pm AEDT.

DVL by the numbers
More From The Market Herald
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon

" Little Green Pharma (ASX:LGP) seeks to expand to Greece

Little Green Pharma (ASX:LGP) seeks to expand to Greece

" HeraMED (ASX:HMD) signs “significant milestone” with a Perth hospital

Digital maternity care company HeraMED (ASX:HMD) has hit a "truly significant milestone" with a Perth hospital,…

" ResApp Health (ASX:RAP) signs LOI to launch diagnostic app in the Philippines

ResApp Health (ASX:RAP) smartphone diagnostic test is set to launch in the Philippines through an agreement…

" Emyria (ASX:EMD) set to begin ultra-pure CBD trial

Emyria (ASX:EMD) is set to begin phase one clinical trials of its ultra-pure CBD drug candidate,…